在肥胖前患有高血压的患者中,脏适应
Agnes Bosch1, Manfred Rauh2, Kristina Striepe1
1Department of Nephrology and Hypertension.
Journal of hypertension
|September 9, 2024
概括
高血压患者的肥胖前期会损害功能,降低膜过率和脏血流量. 这表明低过是对高血压前肥胖症的早期适应.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心血管医学 心血管医学
- 代谢障碍 代谢障碍 代谢障碍
背景情况:
- 肥胖是患有高血压个体慢性病 (CKD) 的已知危险因素.
- 肥胖前期对功能和高血压中的血液动力学影响尚不清楚.
研究的目的:
- 调查腰围或体重指数定义的肥胖前期是否会影响高血压患者的功能, perfusion 和 intraglomerular 血液动力学.
- 在高血压患者和前肥胖症患者中表征脏血液动力学概况.
主要方法:
- 在36名男性高血压患者 (阶段1-2) 中,使用稳定状态清除技术评估了脏血液动力学概况,而无需药物治疗.
- 计算了血球内部压力 (IGP), afferent (RA) 和 efferent (RE) 动脉阻力.
- 根据腰围 (96厘米) 和体重指数 (26.5公斤/米2) 的中位数,患者被分为前肥胖和非肥胖组.
主要成果:
- 肥胖前的高血压患者与非肥胖患者相比,表现出较低的淋巴细胞过率 (GFR) 和脏血流量 (RPF).
- 在前肥胖组中观察到血管阻力 (RVR) 和 afferent动脉阻力 (RA) 的升高.
- 这些血液动力学变化是一致的,不管肥胖前是否被腰围或BMI定义.
结论:
- 高血压患者的肥胖前期与脏血液动力学特征相关,其特征是减少GFR和RPF.
- 增加的RVR,主要在血球前层,是这种特征的特征.
- 在高血压的背景下,低过似乎是脏对肥胖前的初始适应.
更多相关视频
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
Hypertension and Regulation of Blood Pressure
1.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
Hormonal Regulation
33.0K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.0K
Antihypertensive Drugs: Action of β1 Blockers
320
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
320
Hormonal Regulation of Blood Pressure
2.5K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
2.5K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
606
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
606


